Table 2.
Constituent | Study Type | Subjects | Dose | Potential Mechanisms | Ref. |
---|---|---|---|---|---|
6-shogaol | In vitro | HT-29/B6 and Caco-2 human intestinal epithelial cells | 100 μM | Inhibiting the PI3K/Akt and NF-κB signaling pathways | [37] |
6-shogaol and 6-gingerol, 6-dehydroshogaol | In vitro | RAW 264.7 mouse macrophage cells | 2.5, 5, and 10 μM | Inhibiting the production of NO and PGE2 | [36] |
6-gingerol-rich fraction | In vivo | Female Wistar rats | 50 and 100 mg/kg | Increasing the levels of myeloperoxidase, NO, and TNF-α | [25] |
GDNPs 2 | In vivo | Female C57BL/6 FVB/NJ mice |
0.3 mg | Increasing the levels of IL-10 and IL-22; decreasing the levels of TNF-α, IL-6, and IL-1β |
[4] |
Ginger extract and zingerone | In vivo | Female BALB/c mice | 0.1, 1, 10, and 100 mg/kg | Inhibiting NF-κB activation and decreasing the level of IL-1β | [38] |
Ginger extract | In vivo | C57BL6/J mice | 50 mg/mL | Inhibiting the production of TNF-α; Activating Akt and NF-κB |
[39] |
NO, nitric oxide; PGE2, prostaglandin E2; TNF-α, tumor necrosis factor α; GDNPs 2, nanoparticles derived from edible ginger.